Table 1.

Clinical and demographic characteristics of the HPFS (1986–2010) and PHS (1983–2010) Prostate Tumor Cohort

HPFS (n = 475)PHS (n = 330)
Continuous
Age at baseline, mean (SD), y57.7 (7.4)56.3 (7.6)
Age at diagnosis, mean (SD), y65.6 (6.3)66.4 (6.2)
Follow-up, median (range), mo158.0 (1.0–281.0)130.9 (1.0–277.8)
Baseline BMI, median (range), kg/m224.8 (18.6–61.5)24.4 (18.3–35.9)
Mean percent area for PTEN+, mean (SD)0.25 (0.22)0.20 (0.18)
Mean multiplicative score for PTEN+, mean (SD)26.0 (24.4)19.9 (20.1)
Categoricaln (%)n (%)
Outcomes
 Prostate cancer death38 (8.0)25 (7.6)
 Distant metastasis10 (2.1)3 (0.9)
Tumor stage
 pT1b-pT2N0M0323 (68.0)254 (77.0)
 pT3N0M0132 (27.8)63 (19.1)
 pT4/N1/M120 (4.2)13 (3.9)
Gleason grade
 2–695 (20.0)88 (26.8)
 7 (3 + 4)116 (24.4)67 (20.3)
 7 (4 + 3)190 (40.0)120 (36.4)
 8–1074 (15.6)54 (16.4)
(Missing 1 record)
Smoking status
 Never238 (50.1)164 (49.7)
 Past191 (40.2)120 (36.4)
 Current46 (9.7)24 (7.3)
 Missing0 (0)22 (6.7)
PSA at diagnosis
 <448 (10.1)31 (9.4)
 4–10214 (45.1)184 (55.8)
 >10136 (28.6)67 (20.3)
 Missing77 (16.2)48 (14.6)
Year of diagnosis
 Before 1990 (pre-PSA era)35 (7.4)25 (7.6)
 1990–1993 (peri-PSA era)155 (32.6)63 (19.1)
 After 1993 (PSA era)285 (60.0)242 (73.3)